UY25320A1 - Solución acuosa de clorhidrato de 1-(2-(2-naftil)etil)-4-(3-trifluorometilfenil)1,2,3,6-tetrahidropiridina y composición bebible que contiene dicha solución. - Google Patents

Solución acuosa de clorhidrato de 1-(2-(2-naftil)etil)-4-(3-trifluorometilfenil)1,2,3,6-tetrahidropiridina y composición bebible que contiene dicha solución.

Info

Publication number
UY25320A1
UY25320A1 UY25320A UY25320A UY25320A1 UY 25320 A1 UY25320 A1 UY 25320A1 UY 25320 A UY25320 A UY 25320A UY 25320 A UY25320 A UY 25320A UY 25320 A1 UY25320 A1 UY 25320A1
Authority
UY
Uruguay
Prior art keywords
aqueous solution
hydrochloride
solution
trifluorometilfenil
tetrahidropiridina
Prior art date
Application number
UY25320A
Other languages
English (en)
Inventor
Thierry Breul
Marielle Bonnel
Philippe Bastard
Claude Aleman
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY25320A1 publication Critical patent/UY25320A1/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

La presente invención tiene por objeto a una solución acuosa a base de clorhidrato de 1-[2-(2-naftil) etil]-4 (3 trifluorometilfenil)-1,2,3,6-tetrahidropiridina (clorhidrato de SR 57746), que comprende igualmente beta-ciclodextrina (beta-CD) y un ácido o un tampón farmacéuticamente aceptable para asegurar un pH inferior o igual a 3, y una cantidad no nula de clorhidrato de SR 57746. Dicho ácido es elegido entre acético, ascórbico, láctico, succínico, fumárico y cítrico, tal cual se presentan, o incluidos en sistemas tampón. Composición farmacéutica bebible, en unidades de dosificación, caracterizada por que comprende la solución acuosa, en la cual el clorhidrato está presente en una cantidad de 0,5 a 10mg por unidad de dosificación.
UY25320A 1997-12-24 1998-12-21 Solución acuosa de clorhidrato de 1-(2-(2-naftil)etil)-4-(3-trifluorometilfenil)1,2,3,6-tetrahidropiridina y composición bebible que contiene dicha solución. UY25320A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716529A FR2772614B1 (fr) 1997-12-24 1997-12-24 Solution aqueuse a base de chlorhydrate de 1- [ 2-(2-naphtyl)ethyl]-4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine et composition pharmaceutique buvable en contenant

Publications (1)

Publication Number Publication Date
UY25320A1 true UY25320A1 (es) 2000-10-31

Family

ID=9515152

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25320A UY25320A1 (es) 1997-12-24 1998-12-21 Solución acuosa de clorhidrato de 1-(2-(2-naftil)etil)-4-(3-trifluorometilfenil)1,2,3,6-tetrahidropiridina y composición bebible que contiene dicha solución.

Country Status (25)

Country Link
US (1) US6191137B1 (es)
EP (1) EP1041984B1 (es)
JP (1) JP2002510599A (es)
AR (1) AR017722A1 (es)
AT (1) ATE252384T1 (es)
AU (1) AU1880599A (es)
BR (1) BR9814414A (es)
CA (1) CA2315696C (es)
CO (1) CO4970813A1 (es)
DE (1) DE69819203T2 (es)
DK (1) DK1041984T3 (es)
DZ (1) DZ2676A1 (es)
ES (1) ES2209238T3 (es)
FR (1) FR2772614B1 (es)
GT (1) GT199800204A (es)
HU (1) HUP0101012A3 (es)
MY (1) MY117156A (es)
NO (1) NO20003284L (es)
PT (1) PT1041984E (es)
SA (2) SA99191002B1 (es)
SI (1) SI1041984T1 (es)
TW (1) TW536409B (es)
UY (1) UY25320A1 (es)
WO (1) WO1999033466A1 (es)
ZA (1) ZA9811824B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.

Also Published As

Publication number Publication date
DE69819203T2 (de) 2004-07-15
CO4970813A1 (es) 2000-11-07
DZ2676A1 (fr) 2004-09-19
FR2772614A1 (fr) 1999-06-25
CA2315696A1 (en) 1999-07-08
AU1880599A (en) 1999-07-19
HUP0101012A2 (hu) 2001-08-28
NO20003284L (no) 2000-08-24
SA99191002B1 (ar) 2006-03-07
ES2209238T3 (es) 2004-06-16
WO1999033466A1 (fr) 1999-07-08
PT1041984E (pt) 2004-02-27
JP2002510599A (ja) 2002-04-09
DK1041984T3 (da) 2004-02-16
DE69819203D1 (de) 2003-11-27
ZA9811824B (en) 1999-06-29
TW536409B (en) 2003-06-11
AR017722A1 (es) 2001-09-12
CA2315696C (en) 2008-01-29
BR9814414A (pt) 2000-10-10
MY117156A (en) 2004-05-31
EP1041984B1 (fr) 2003-10-22
FR2772614B1 (fr) 2000-03-10
GT199800204A (es) 2000-06-14
ATE252384T1 (de) 2003-11-15
US6191137B1 (en) 2001-02-20
SA99191003B1 (ar) 2006-10-02
NO20003284D0 (no) 2000-06-22
EP1041984A1 (fr) 2000-10-11
HUP0101012A3 (en) 2002-12-28
SI1041984T1 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
ATE195117T1 (de) 1-amdinophenyl-pyrrolidone/piperidinone als blutblättchen-aggregations inhibitoren
RU97102050A (ru) Гетероциклические антагонисты тахикининовых рецепторов
IL115040A0 (en) Novel substituted piperidines useful for the treatment of allergic diseases
TR200100671T1 (tr) Antiviral indoloksoasetil piperazin türevleri
YU9802A (sh) Inhibitori ćelijske adhezije
MXPA05005895A (es) Composicion farmaceutica de 1-(3, 4-dimetoxifenil)-4 -metil-5-etil -7-metoxi-8 -hidroxi- 5h-2, 3-benzodiacepina y usos de la misma.
WO2001062737A3 (en) Amino pyrazole derivatives useful for the treatment of obesity and other disorders
ES2167463T3 (es) Componentes de un compuesto medicinal que comprenden derivados n-sustituidos de la o-toluidina y preparacion percutaneamente absorbible.
IL163896A0 (en) Piperidine or 8-aza-bicycloÄ3.2.1Üoct-3-yl derivatives useful as modulators of chemokine receptoractivity (especially ccr5)
IL124091A (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it
NZ300942A (en) 1-aryl-2-acylamino-ethane derivatives as neurokinin 1 antagonists
MXPA04001364A (es) Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo.
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
UY25320A1 (es) Solución acuosa de clorhidrato de 1-(2-(2-naftil)etil)-4-(3-trifluorometilfenil)1,2,3,6-tetrahidropiridina y composición bebible que contiene dicha solución.
MXPA05011064A (es) Combinaciones de paroxetina y [1-(r)-(3, 5-bis-trifluorometi l-fenil)-etil] -metilamida del acido 4-(s)- (4-acetil-piperazin -1-il)-2- (r)-(4-fluoro -2-metil- fenil)-piperidin -1-carboxilico para tratamiento de depresion y/o ansiedad.
SE0103795D0 (sv) Compounds and method for the treatment of överactive bladder
PT1551827E (pt) Derivados de piperidina como inibidores de ccr5
TH43890A (th) สารดื่มทางเภสัชกรรม
CA2275593A1 (en) Micro-particulate form of a tetrahydropyridin derivative
HRP970701B1 (en) Micro-particulate form of a tetrahydropyridin derivative
ES2063700A1 (es) Agente activo sobre el sistema nervioso central, proceso para su preparacion y composiciones farmaceuticas que lo contengan.
MX9302210A (es) Nuevos derivados de arilpiperidina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
MY138934A (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride

Legal Events

Date Code Title Description
VENC Patent expired

Effective date: 20181221